Humacyte (HUMA) vs Tiziana Life Sciences (TLSA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Tiziana Life Sciences (TLSA) has outperformed Humacyte (HUMA) over the past year, losing 49.3% versus a loss of 71.3%. Over five years, TLSA leads with a -27.2% price change compared with -95.4% for HUMA. Tiziana Life Sciences is the larger company by market cap ($140.0 million vs $131.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HUMA | TLSA |
|---|---|---|
| Share price | $0.4723 | $1.10 |
| Market cap | $131.20M | $139.99M |
| 1-day change | -1.19% | -0.90% |
| YTD return | -50.85% | -26.17% |
| 1-year return | -71.29% | -49.31% |
| 5-year return | -95.38% | -27.15% |
| EPS (TTM) | $-0.51 | $-0.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.90 | $2.33 |
| 52-week low | $0.46 | $0.76 |
| Distance from 52-week high | -75.08% | -52.79% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +245.12% | +625.45% |
| Average volume | 6.35M | 712.06K |
| Shares outstanding | 277.80M | 127.26M |
| Employees | 184 | 10 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TLSA has outperformed HUMA by 22.0 percentage points over the past year.
About Humacyte
HUMA stock →Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 184 employees
About Tiziana Life Sciences
TLSA stock →Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
HUMA vs TLSA FAQ
Which is bigger, Humacyte or Tiziana Life Sciences?
Tiziana Life Sciences (TLSA) is larger, with a market capitalization of $139.99M compared with $131.20M for Humacyte (HUMA).
Which stock has performed better over the past year, HUMA or TLSA?
TLSA returned -49.31% over the past 12 months, compared with -71.29% for HUMA (price return, excluding dividends). Past performance does not predict future results.
Are Humacyte and Tiziana Life Sciences in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Humacyte and Biotechnology: Pharmaceutical Preparations for Tiziana Life Sciences.